Trials / Conditions / Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
3 registered clinical trials studyying Resectable Gastric or Gastroesophageal Junction Adenocarcinoma — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Bl NCT06649474 | University Hospital, Clermont-Ferrand | N/A |
| Recruiting | Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junc NCT05960955 | Akeso | Phase 2 |
| Completed | Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab P NCT04221555 | Asan Medical Center | Phase 2 |